Usefulness of determination of β-D-glucan in the diagnosis of deep mycosis – experience in Japan

References

• Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071–1079
   PubMed Web of Science ®Google Scholar
• Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781–805
   PubMed Web of Science ®Google Scholar
• Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis, disease spectrum, treatment practices, and outcomes. Medicine 2000; 79: 250–260
   PubMed Web of Science ®Google Scholar
• Nucci M, Marr KA, Oueiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38: 1237–1242
   PubMed Web of Science ®Google Scholar
• Matsue K, Uryu H, Koseki M, et al. Breakthrough trichospornosis in patients with hematologic malignancies receiving Micafungin. Clin Infect Dis 2006; 42: 753–757
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634–653
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Kohno S, Mitsutake K, et al. Plasma (1→3)-β-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. J Clin Microbiol 1995; 33: 3115–3118
   PubMed Web of Science ®Google Scholar
• Ohbayashi T, Yoshida M, Tamura H, et al. Determination of plasma (1→3)-β-D-glucan: a new diagnostic aid to deep mycosis. J Med Vet Mycol 1992; 30: 275–280
   PubMedGoogle Scholar
• Morita T, Tanaka S, Nakamura T, et al. A new (1→3)-β-D-glucan-mediated coagulation pathway found in limulus amebocytes. FEBS Letters 1981; 129: 318–321
   Web of Science ®Google Scholar
• Obayashi T, Tamura H, Tanaka S, et al. A new chromogenic endotoxin-specific assay using recombined limulus coagulation enzymes and its clinical applications. Clin Chim Acta 1985; 149: 55–65
   PubMed Web of Science ®Google Scholar
• Yoshida M, Obayashi T, Tamura H, et al. Diagnostic and prognostic significance of plasma endotoxin determination in febrile patients with haematological malignancies. Eur J Cancer 1994; 30A: 145–147
   PubMed Web of Science ®Google Scholar
• Obayashi T, Yoshida M, Mori T, et al. Plasma (1→3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345: 17–20
   PubMed Web of Science ®Google Scholar
• Iwama A, Yoshida M, Miwa A, et al. Improved survival from fungaemia in patients with haematological malignancies: analysis of risk factors for death and usefulness of early antifungal therapy. Eur J Haematol 1993; 51: 156–160
   PubMed Web of Science ®Google Scholar
• Yoshida M, Obayashi T, Iwama A, et al. Detection of plasma (1→3)-β-D-glucan in patients with Fusarium, Trichosporon, Saccharomyces, and Acremonium fungemias. J Med Veter Mycol 1997; 35: 371–374
   PubMedGoogle Scholar
• Yoshida M, Ohno R. Current antimicrobial usage for the management of infections in leukemic patients in Japan: Results of a survey. Clin Infect Dis 2004; 39(Suppl. 1)S11–S14
   PubMedGoogle Scholar
• Kami M, Fukui T, Ogawa S, et al. Real-time polymerase chain reaction using blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 2001; 33: 1504–1512
   PubMed Web of Science ®Google Scholar
• Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641–649
   PubMed Web of Science ®Google Scholar
• Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1→3)-β-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004; 42: 2733–2741
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20: 1898–1906
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14
   PubMed Web of Science ®Google Scholar
• Uchida K, Nishiyama Y, Yokota N, et al. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot (Tokyo) 2000; 53: 1175–1181
   PubMed Web of Science ®Google Scholar
• Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730–751
   PubMed Web of Science ®Google Scholar
• Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis 2004; 39(Suppl. 1)S49–S52
   Web of Science ®Google Scholar
• The guidelines for the diagnosis and treatment of deep mycosis, 1st edn. Tokyo: Ishiyaku Shuppan, 2003: 1–47. [In Japanese].
   Google Scholar
• Pizzo PA, Robichaud KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101–111
   PubMed Web of Science ®Google Scholar
• EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86: 668–672.
   PubMed Web of Science ®Google Scholar
• Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2004; 39(Suppl. 1)S38–S43
   PubMed Web of Science ®Google Scholar
• Kato A, Takita T, Furuhashi M, et al. Elevation of blood (1→3)-β-D-glucan concentrations in hemodialysis patients. Nephron 2001; 89: 15–19
   PubMed Web of Science ®Google Scholar
• Nakao A, Yasui M, Kawagoe T, et al. False-positive endotoxemia derives from gauze glucan after hepatectomy for hepatocellular carcinoma with cirrhosis. Hepatogastroenterology 1997; 44: 1413–1418
   PubMed Web of Science ®Google Scholar
• Ikemura K, Ikegami K, Shimazu T, et al. False-positive result in Limulus test caused by Limulus amebocyte lysate-reactive material in immunoglobulin products. J Clin Microbiol 1989; 27: 1965–1968
   PubMed Web of Science ®Google Scholar
• Ogawa M, Hori H, Niiguchi S, et al. False-positive plasma (1→3)-β-D-glucan test following immunoglobulin product replacement in an adult bone marrow recipient. Int J Hematol 2004; 80: 97–98
   PubMed Web of Science ®Google Scholar
• Ishizuka Y, Tsukada H, Gejyo F. Interference of (1→3)-β-D-glucan administration in the measurement of plasma (1→3)-β-D-glucan. Intern Med 2004; 43: 97–101
   PubMed Web of Science ®Google Scholar
• Yoshida, K, Niki, Y, Matsuda, J, , et al. Evaluation of an improvement method for the measurement of (1→3)-β-D-glucan in blood samples. J A Inf Dis 2005; 79: 433–442. [In Japanese].
   Google Scholar
• Mori T, Ikemoto H, Matsumura M, et al. Evaluation of plasma (1→3)-β-D-glucan measurement by kinetic turbidimetric Limulus test, for the clinical diagnosis of mycotic infection. Eur J Chem Clin Biochem 1997; 35: 553–560
   PubMedGoogle Scholar
• Hossain MA, Miyazaki T, Mitsutake K, et al. Comparison between Wako-WB003 and Fungitec G tests for detection of (1→3)-β-D-glucan in systemic mycosis. J Clin Lab Anal 1997; 11: 73–77
   PubMed Web of Science ®Google Scholar
• Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743–746
   PubMed Web of Science ®Google Scholar
• Yasuoka A, Tachikawa N, Shimada K, et al. (1→3)-β-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 1996; 3: 197–199
   PubMedGoogle Scholar
• Odabasi Z, Mattiuzzi G, Estey E, et al. β-D-Glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199–205
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1→3)-β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654–659
   PubMed Web of Science ®Google Scholar
• Pazos C, Ponton J, Palacio AD. Contribution of (1→3)-β-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of inva-sive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43: 299–305
   PubMed Web of Science ®Google Scholar
• Pickering JW, Sant HW, Bowles CAP, et al. Evaluation of a (1→3)-β-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43: 5957–5962
   PubMed Web of Science ®Google Scholar